Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet E Pope

Showing results (61-70 of 299) with videos related to

Pageof 30
Sort By:
Frontiers in Immunology|May 23, 2022
Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue DiseasesLeonardo Martin Calderon, Janet E Pope
The Journal of Rheumatology|November 5, 2002
Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritisJanet E Pope, Mala Joneja, Paul Hong
Rheumatology (Oxford, England)|March 25, 2017
Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohortTatiana Nevskaya, Murray Baron, Janet E Pope, et al.
Seminars in Arthritis and Rheumatism|December 3, 2014
The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world studyJanet E Pope, Emmanouil Rampakakis, John Sampalis
The Journal of Rheumatology|January 6, 2004
The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritisJanet E Pope, Mark Prashker, Jennifer Anderson
The Journal of Rheumatology|June 3, 2009
Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaireLillian Barra, Janet E Pope, Michael Payne
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
Current Opinion in Rheumatology|October 14, 2024
Polymyalgia rheumatica and giant cell arteritis: diagnosis and managementMargaret Man-Ger Sun, Janet E Pope
Immunotherapy|April 9, 2019
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature reviewJehanya Jegatheeswaran, Matthew Turk, Janet E Pope
The Open Rheumatology Journal|July 30, 2009
Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic NaiveEmily McKeown, Janet E Pope, Suzanne Leaf
Pageof 30

Showing results (61-70 of 299) with videos related to

Sort By:
Pageof 30
Frontiers in Immunology|May 23, 2022
Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue DiseasesLeonardo Martin Calderon, Janet E Pope
The Journal of Rheumatology|November 5, 2002
Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritisJanet E Pope, Mala Joneja, Paul Hong
Rheumatology (Oxford, England)|March 25, 2017
Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohortTatiana Nevskaya, Murray Baron, Janet E Pope, et al.
Seminars in Arthritis and Rheumatism|December 3, 2014
The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world studyJanet E Pope, Emmanouil Rampakakis, John Sampalis
The Journal of Rheumatology|January 6, 2004
The efficacy and cost effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal antiinflammatory drugs in osteoarthritisJanet E Pope, Mark Prashker, Jennifer Anderson
The Journal of Rheumatology|June 3, 2009
Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaireLillian Barra, Janet E Pope, Michael Payne
Arthritis & Rheumatology (Hoboken, N.J.)|March 29, 2021
Current Treatment Strategies in Rheumatoid Arthritis After Methotrexate Are Not Enough to Maintain Sustained Remission: There Is No Holy Grail!Janet E Pope, Peter Nash, Roy Fleischmann
Current Opinion in Rheumatology|October 14, 2024
Polymyalgia rheumatica and giant cell arteritis: diagnosis and managementMargaret Man-Ger Sun, Janet E Pope
Immunotherapy|April 9, 2019
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature reviewJehanya Jegatheeswaran, Matthew Turk, Janet E Pope
The Open Rheumatology Journal|July 30, 2009
Epstein-Barr Virus (EBV) Prevalence and the Risk of Reactivation in Patients with Inflammatory Arthritis Using Anti-TNF Agents and in those who are Biologic NaiveEmily McKeown, Janet E Pope, Suzanne Leaf
Pageof 30